Opticyte Analysis: $5M Raised
What is Opticyte?
Opticyte develops the VitalO₂ device, the first to measure oxygen levels inside cells in real-time. This technology aims to improve early detection and treatment of sepsis and other conditions leading to organ failure. The device has received Breakthrough Device Designation from the FDA for its potential to enhance patient outcomes.
Location
4000 Mason Rd, Seattle, Washington 98195, United States
Employees
1-10
Founded
2016
Funding Status
Seed
Product Features & Capabilities
- VitalO₂ device for real-time cellular oxygen monitoring
- FDA-recognized breakthrough device for sepsis detection
- Machine learning algorithms for diverse skin tones
Use Cases
Monitor oxygen levels in emergency departments; Assess cellular oxygen in intensive care units; Aid in surgical settings for real-time data; Support clinicians in diagnosing sepsis; Provide actionable data for trauma care
Other Considerations
Recognized by the FDA as a Breakthrough Device; Addresses racial disparities in pulse oximetry; Potential to prevent 80% of sepsis-related deaths; Significant financial burden of sepsis treatment in the U.S.
See something that needs updating? Suggest edits to this profile.